| 1 |
NCT03142217 |
Withdrawn |
Characterization of the Profile of Dysarthria in Huntington's Disease, Using the Clinical Evaluation Battery of Dysarthria |
- Dysarthria
- Huntington Disease
|
- Other: Study of dysarthria in patients with Huntington's disease
|
Interventional |
Not Applicable |
- Centre Hospitalier Universitaire, Amiens
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Analysis of the Clinical Evaluation Battery of Dysarthria using criteria to establish a clinical profile specific to Huntington's disease
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT03142217 |
PI2015_843_0005 |
Huntington |
March 26, 2015 |
March 1, 2017 |
March 1, 2017 |
May 5, 2017 |
May 5, 2017 |
|
|
| 2 |
NCT01554033 |
Unknown † |
Study of Huntington Patients in Connection With European Huntington's Disease Network (EHDN) |
|
|
Observational |
|
- Seoul National University Hospital
- European Huntington's Disease Network
|
Other |
- Observational Model: Case-Crossover
- Time Perspective: Cross-Sectional
|
|
200 |
All |
1 Year to 80 Years (Child, Adult, Senior) |
NCT01554033 |
H-0902-023-271 |
|
May 2009 |
May 2015 |
May 2015 |
March 14, 2012 |
March 19, 2012 |
|
- Department of Neurology, Seoul National University Hospital
Seoul, Korea, Republic of
|
| 3 |
NCT02876445 |
Completed |
Caregiver Burden in Huntington's Disease |
- Caregiver of Huntington's Disease Patient
|
- Other: ZARIT Burden Interview
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Evaluation with ZARIT's scale of the burden level of the management of a patient with Huntington's disease by his caregiver
- Measuring social impact of the disease using the under score of ZARIT's scale for the patient and the caregiver
- Measuring professional impact of of the disease using the under score of ZARIT's scale for the patient and the caregiver
|
179 |
All |
18 Years and older (Adult, Senior) |
NCT02876445 |
NI10059 |
PHRI-HD |
March 2011 |
March 2016 |
March 2016 |
August 23, 2016 |
August 23, 2016 |
|
- Henri Mondor Hospital
Creteil, France
|
| 4 |
NCT02006472 |
Completed |
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease |
|
- Drug: Pridopidine
- Other: Placebo
|
Interventional |
Phase 2 |
- Teva Branded Pharmaceutical Products, R&D Inc.
- European Huntington's Disease Network
- Huntington Study Group
- Teva Pharmaceutical Industries
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at week 26
- Change from Baseline in modified Physical Performance Test (mPPT)
- Summary of participants with Adverse Events
|
408 |
All |
21 Years and older (Adult, Senior) |
NCT02006472 |
TV7820-CNS-20002
2013-001888-23 |
|
February 28, 2014 |
July 31, 2016 |
August 31, 2016 |
December 10, 2013 |
February 20, 2018 |
|
- Teva Investigational Site 12199
La Jolla, California, United States - Teva Investigational Site 12204
Los Angeles, California, United States - Teva Investigational Site 12201
Englewood, Colorado, United States - (and 55 more...)
|
| 5 |
NCT03342053 |
Not yet recruiting |
Study in Huntington's Disease Patients Who Participated in Prior Investigational Studies of ISIS 443139 |
|
|
Interventional |
Phase 2 |
- Ionis Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of treatment-emergent adverse events [safety and tolerability]
|
46 |
All |
25 Years and older (Adult, Senior) |
NCT03342053 |
ISIS 443139-CS2 |
|
November 2017 |
September 30, 2019 |
September 30, 2019 |
November 14, 2017 |
November 27, 2017 |
|
- University of British Columbia
Vancouver, British Columbia, Canada - Charite University Berlin
Berlin, Germany - Ruhr-University of Bochum
Bochum, Germany - (and 6 more...)
|
| 6 |
NCT01306929 |
Completed |
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease |
|
|
Interventional |
Phase 2 |
- Teva Branded Pharmaceutical Products, R&D Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of subjects with at least one adverse event
- Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score
|
235 |
All |
Child, Adult, Senior |
NCT01306929 |
ACR16C015 |
OPEN-HART |
March 1, 2011 |
January 5, 2018 |
January 5, 2018 |
March 2, 2011 |
March 14, 2018 |
|
- Teva Investigational Site 045
Indianapolis, Indiana, United States - Teva Investigational Site 024
Iowa City, Iowa, United States - Teva Investigational Site 028
Baltimore, Maryland, United States - (and 9 more...)
|
| 7 |
NCT01485965 |
Completed |
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease |
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the effect of food on the repeated dose pharmacokinetics of SEN0014196 at 100 mg once daily in subjects with Huntington's disease
- Pharmacodynamics
- To determine the safety and tolerability of repeated doses of SEN0014196 at 100 mg once daily in subjects with Huntington's disease
|
26 |
All |
25 Years to 65 Years (Adult) |
NCT01485965 |
S015-007 |
|
November 2011 |
November 2012 |
December 2012 |
December 6, 2011 |
March 20, 2013 |
|
- University of California San Diego
La Jolla, California, United States - University of California Davis Medical Center
Sacramento, California, United States - Washington University
St. Louis, Missouri, United States - (and 4 more...)
|
| 8 |
NCT01485952 |
Completed |
An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196 |
|
- Drug: SEN0014196 (Low Dose)
- Drug: SEN0014196 (High Dose)
- Drug: Placebo
|
Interventional |
Phase 1 |
- Siena Biotech S.p.A.
- Seventh Framework Programme
- European Huntington's Disease Network
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To determine the change from baseline of a series of pharmacodynamic markers in peripheral blood mononuclear cells
- To determine the safety and tolerability following repeated doses of SEN0014196 over two weeks at two dose levels in patients with Huntington's disease
- To determine the pharmacokinetics of repeated doses of SEN0014196 at two dose levels when administered over two weeks in patients with Huntington's disease
|
55 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01485952 |
S015-004
CTA Number: 2010-021563-32 |
PADDINGTON |
March 2011 |
November 2011 |
November 2011 |
December 6, 2011 |
November 25, 2015 |
|
- Universitätsklinik Ulm, Neurologie
Ulm, Germany
|
| 9 |
NCT02494778 |
Completed |
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease |
|
|
Interventional |
Phase 2 |
- Teva Branded Pharmaceutical Products, R&D Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of participants with adverse events
- Proportion of subjects (%) who prematurely discontinued from the study
- Proportion of subjects (%) who prematurely discontinued from the study due to AEs
|
248 |
All |
21 Years and older (Adult, Senior) |
NCT02494778 |
TV7820-CNS-20016
2015-000904-24 |
Open PRIDE-HD |
September 15, 2015 |
January 15, 2018 |
January 15, 2018 |
July 10, 2015 |
April 24, 2018 |
|
- Teva Investigational Site 12204
Los Angeles, California, United States - Teva Investigational Site 12201
Englewood, Colorado, United States - Teva Investigational Site 12196
Washington, District of Columbia, United States - (and 42 more...)
|
| 10 |
NCT00497159 |
Completed |
A Study of the Novel Drug Dimebon in Patients With Huntington's Disease |
|
- Other: Placebo
- Drug: Dimebon
|
Interventional |
Phase 2 |
- Medivation, Inc.
- Huntington Study Group
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To assess the safety and tolerability of Dimebon during 3 months of treatment in subjects with Huntington's Disease.
- To assess the impact of Dimebon during 3 months of treatment on cognitive, motor, and overall function in subjects with Huntington's Disease.
- To assess the pharmacokinetics of Dimebon.
|
91 |
All |
29 Years and older (Adult, Senior) |
NCT00497159 |
DIM05 |
DIMOND |
July 2007 |
June 2008 |
June 2008 |
July 6, 2007 |
June 8, 2015 |
|
- Huntington Study Group
Rochester, New York, United States
|
| 11 |
NCT02263430 |
Not yet recruiting |
PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease |
|
- Device: Deep Brain Stimulation
|
Interventional |
Not Applicable |
- Beijing Pins Medical Co., Ltd
- Beijing Tiantan Hospital
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Unified Huntington's Disease Rating Scale(UHDRS)
|
8 |
All |
18 Years and older (Adult, Senior) |
NCT02263430 |
PINS-007 |
|
December 2016 |
December 2018 |
December 2018 |
October 13, 2014 |
October 14, 2016 |
|
|
| 12 |
NCT02728115 |
Not yet recruiting |
Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease |
|
- Biological: Cellavita HD Lower Dose
- Biological: Cellavita HD Higher dose
|
Interventional |
Phase 1 |
- Azidus Brasil
- Cellavita Pesquisa Científica Ltda
- Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Safety of Cellavita HD by periodic monitoring changes at adverse events, vital signs, laboratory tests, ECG and incidence of benign and malignant neoplasms
- Preliminary efficacy of Cellavita HD by global clinical response and UHDRS improvement
- Preliminary efficacy of Cellavita HD by comparison of the inflammatory markers
- (and 4 more...)
|
6 |
Male |
21 Years to 65 Years (Adult) |
NCT02728115 |
SAVE-DH
51005115.9.0000.5412 |
SAVE-DH |
October 2017 |
October 2022 |
February 2023 |
April 5, 2016 |
August 16, 2017 |
|
|
| 13 |
NCT02197130 |
Completed
Has Results |
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease |
|
- Drug: PF-02545920
- Other: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Total Motor Score (TMS) Assessment of the Unified Huntington Disease Rating Scale (UHDRS) After 26 Weeks of Treatment.
- Number of Participants That Met White Blood Count (WBC) and Absolute Neutrophil Count (ANC) Stopping Criteria
- Number of Participants With Adverse Events
- (and 12 more...)
|
272 |
All |
30 Years to 65 Years (Adult) |
NCT02197130 |
A8241021
2014-001291-56 |
|
September 2014 |
September 2016 |
October 2016 |
July 22, 2014 |
November 17, 2017 |
November 17, 2017 |
- The Kirklin Clinic of UAB Hospital
Birmingham, Alabama, United States - The University of Alabama at Birmingham
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - (and 54 more...)
|
| 14 |
NCT01412125 |
Recruiting |
Study of Biomarkers That Predict the Evolution of Huntington's Disease |
|
- Other: Huntington patient evaluation
- Other: Healthy subject evaluation
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Unified Huntington Disease Rating Scale (UHDRS)
- Mattis Dementia Rating Scale
- Trail Making test A et B
- (and 8 more...)
|
1800 |
All |
18 Years and older (Adult, Senior) |
NCT01412125 |
P090302 |
BIOHD |
September 2003 |
January 2021 |
January 2021 |
August 9, 2011 |
October 9, 2014 |
|
- Hôpital Henri Mondor
Creteil, France
|
| 15 |
NCT02563418 |
Unknown † |
Feasibility of a Video-oculography in Patients With Huntington's Disease VOG-HD Study |
|
|
Interventional |
Not Applicable |
- University Hospital, Angers
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- saccadic measures with the eye tracker
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT02563418 |
AOI 2013 - 11 |
VOG-HD |
May 2014 |
May 2017 |
|
September 30, 2015 |
September 30, 2015 |
|
- Centre Hospitalier Universitaire
Angers, France
|
| 16 |
NCT01879267 |
Recruiting |
Exercise Effects in Huntington's Disease |
|
- Behavioral: Exercise training
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Unified Huntington's Disease Rating Scale (UHDRS)
|
40 |
Male |
30 Years to 60 Years (Adult) |
NCT01879267 |
KEK-ZH-Nr. 2009-0119 |
|
January 2012 |
January 2018 |
January 2018 |
June 17, 2013 |
July 19, 2017 |
|
- University Hospital Zurich, Division of Neurology
Zurich, ZH, Switzerland
|
| 17 |
NCT03119246 |
Recruiting |
Beta Testing of a New Assessment in Huntington's Disease (HD) |
|
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
- School of Biosciences - Cardiff University
- University Hospital of Wales
- (and 4 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- All dysfunction or disorder of huntington patient measured by means of a new battery assessments
- Difference on motor score between patient and healthy volontary measured by motor tests of the revised Core Assessment Protocol
- Difference on cognitive score between patient and healthy volontary measured by cognitive tests of the revised Core Assessment Protocol
- (and 3 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT03119246 |
P150201 |
CAPIT-HD Beta |
June 2016 |
March 2018 |
March 2018 |
April 18, 2017 |
April 18, 2017 |
|
- Henri Mondor Hospital
Creteil, France
|
| 18 |
NCT03252535 |
Not yet recruiting |
Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease |
|
- Biological: Cellavita HD lower dose
- Biological: Cellavita HD higher dose
- Other: Placebo
|
Interventional |
Phase 2 |
- Azidus Brasil
- Cellavita Pesquisa Científica Ltda
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Effective Dose
- Improvement of UHDRS domains
- Clinical worsing over the treatment
- (and 3 more...)
|
35 |
All |
21 Years to 65 Years (Adult) |
NCT03252535 |
ADORE-DH
52375916.1.0000.5412 |
ADORE-DH |
April 15, 2018 |
April 15, 2020 |
September 30, 2020 |
August 17, 2017 |
August 17, 2017 |
|
|
| 19 |
NCT02639871 |
Recruiting |
Dynamic Neuroimaging Biomarkers in Huntington's Disease |
- Brain Neuroimaging Biomarkers in Huntington Disease
|
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
- CEA
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Cerebral synthesis rate of creatine phosphate
- Cerebral brain glutamate concentrations
- Cerebral pH values.
- (and 11 more...)
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT02639871 |
P140708
2015-A00793-46 |
HDeNERGY |
June 28, 2016 |
June 2018 |
September 2018 |
December 28, 2015 |
November 30, 2017 |
|
- APHP - Pitié Salpetriere Hospital
Paris, France
|
| 20 |
NCT02926820 |
Completed |
Working Memory Training in Huntington's Disease |
|
|
Interventional |
Not Applicable |
- York University
- North York General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adherence to training (defined by completing the intervention within the recommended time frame)
- Digit Span subtest from the Wechsler Memory Scales - third edition
- Spatial Span subtest from the Wechsler Memory Scales - third edition
- (and 6 more...)
|
9 |
All |
20 Years to 65 Years (Adult) |
NCT02926820 |
NYGH 15-0001 |
|
February 2015 |
March 2016 |
March 2016 |
October 6, 2016 |
October 10, 2016 |
|
- North York General Hospital
Toronto, Ontario, Canada
|
| 21 |
NCT01019473 |
Terminated |
Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea |
- Huntington's Disease
- Chorea
|
- Drug: AFQ056
- Drug: Placebo
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Efficacy of AFQ056 on the severity of chorea in Huntington's disease measured by Unified Huntington's Disease Rating Scale (UHDRS) Maximal Chorea score.
- Potential effect of AFQ056 on the motor, cognitive, behavioral and functional assessments using UHDRS.
- Potential effect of AFQ056 on functional and quality of life scales, neuropsychiatric assessments and cognitive assessments in Huntington's Disease patients
|
44 |
All |
30 Years to 85 Years (Adult, Senior) |
NCT01019473 |
CAFQ056A2207
2009-011743-39 |
|
November 2009 |
August 2011 |
|
November 25, 2009 |
September 23, 2011 |
|
- Novartis Investigator Site
Berlin, Germany - Novartis Investigator Site
Bochum, Germany - Novartis Investigator Site
Munster, Germany - (and 7 more...)
|
| 22 |
NCT02519036 |
Active, not recruiting |
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in Patients With Early Manifest Huntington's Disease |
|
- Drug: IONIS HTTRx
- Drug: Placebo
|
Interventional |
Phase 1
Phase 2 |
- Ionis Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Safety (The number of participants with adverse events)
- Tolerability (The number of participants with adverse events)
- CSF Pharmacokinetics (The observed CSF drug concentration)
|
46 |
All |
25 Years to 65 Years (Adult) |
NCT02519036 |
ISIS 443139-CS1 |
|
August 31, 2015 |
July 31, 2017 |
November 30, 2017 |
August 10, 2015 |
June 26, 2017 |
|
- University of British Columbia
Vancouver, British Columbia, Canada - Charite University Berlin
Berlin, Germany - Ruhr-University of Bochum
Bochum, Germany - (and 6 more...)
|
| 23 |
NCT02509793 |
Recruiting |
A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine) |
|
|
Interventional |
Phase 4 |
- William Ondo, MD
- H. Lundbeck A/S
- The Methodist Hospital System
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Score on the Questionnaire for Impulsive Disorders in Parkinson's Disease
- Change in Score on the Geriatric Depression Scale
- Change in Score on the Barrat Impulsivity Scale
- (and 4 more...)
|
20 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02509793 |
Pro00013929
HSC-MS-13-0878 |
|
April 2014 |
July 2018 |
July 2018 |
July 28, 2015 |
August 11, 2017 |
|
- Methodist Neurological Institute
Houston, Texas, United States
|
| 24 |
NCT01502046 |
Completed |
Neuroprotection by Cannabinoids in Huntington's Disease |
|
- Drug: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
- Drug: Placebo
|
Interventional |
Phase 2 |
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
- GW Pharmaceuticals Ltd.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Serious Adverse Events reported
- Changes in the UHDRs Score
- Changes in the BDNF levels (Brain-derived Neurotrophic Factor), oxidative stress (due to mitochondrial dysfunction) and proinflammatory cytokines in plasma
- Changes in the BDNF levels (Brain-derived Neurotrophic Factor), oxidative stress (due to mitochondrial dysfunction) and proinflammatory cytokines in cerebrospinal fluid.
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT01502046 |
SAT-HD
2010-024227-24 |
|
September 2011 |
June 2012 |
June 2012 |
December 30, 2011 |
February 1, 2013 |
|
- Hospital Universitario Ramón y Cajal
Madrid, Spain
|
| 25 |
NCT03296176 |
Recruiting |
Metabolomic Study in Huntington's Disease (METABO-HD) |
|
|
Interventional |
Not Applicable |
- University Hospital, Angers
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
|
150 |
All |
20 Years to 70 Years (Adult, Senior) |
NCT03296176 |
49RC17_0086 |
|
October 9, 2017 |
September 2019 |
September 2019 |
September 28, 2017 |
November 1, 2017 |
|
|
| 26 |
NCT01590589 |
Completed |
REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN) |
- Huntington Disease
- Huntington's Disease
|
|
Observational |
|
- European Huntington's Disease Network
- European Huntington's Disease Network
|
Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Phenotypical characteristics of HD
|
10000 |
All |
Child, Adult, Senior |
NCT01590589 |
REGISTRY 3.0 |
REGISTRY |
June 2004 |
June 30, 2017 |
June 30, 2017 |
May 3, 2012 |
September 15, 2017 |
|
- Universitätsklinik für Psychiatrie, Neuropsychiatrische Ambulanz
Graz, Austria - Universitätsklinik Innsbruck, Neurologie
Innsbruck, Austria - UCL-St Luc, Centre de génétique humaine
Brussels, Belgium - (and 137 more...)
|
| 27 |
NCT01860339 |
Recruiting |
Growth and Development of the Striatum in Huntington's Disease |
|
|
Observational |
|
- Peggy C Nopoulos
- CHDI Foundation, Inc.
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Iowa
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Volume of brain structures as measured by Magnetic Resonance Imaging (MRI)
- Quantitative assessment of cognitive skills and motor skills
|
400 |
All |
6 Years to 18 Years (Child, Adult) |
NCT01860339 |
200507759
4R01NS055903-08 |
Kids-HD |
July 2005 |
August 2018 |
|
May 22, 2013 |
June 1, 2017 |
|
- University of Iowa Hospitals and Clinics, Department of Psychiatry
Iowa City, Iowa, United States
|
| 28 |
NCT02342548 |
Terminated
Has Results |
Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021 |
|
- Drug: 20 mg BID of PF-02545920
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events
- Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
- Number of Participants With Vital Signs Data Meeting Categorical Summarization Criteria
- (and 8 more...)
|
188 |
All |
30 Years to 66 Years (Adult, Senior) |
NCT02342548 |
A8241022
2014-004900-31
OPEN LABEL TO A8241021 |
|
February 25, 2015 |
February 6, 2017 |
February 6, 2017 |
January 21, 2015 |
April 23, 2018 |
April 23, 2018 |
- The Kirkland Clinic of UAB Hospital
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - (and 47 more...)
|
| 29 |
NCT00724048 |
Completed |
A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease |
|
- Drug: ACR16 10 mg
- Drug: ACR16 22.5 mg
- Drug: ACR16 45 mg
- Other: Placebo
|
Interventional |
Phase 2
Phase 3 |
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Sum score of items 4-10 and 13-15 of the UHDRS motor assessment
- Clinical Global Impressions (CGI)
- Adverse event profile
|
227 |
All |
30 Years and older (Adult, Senior) |
NCT00724048 |
ACR16 C009 |
HART |
October 2008 |
June 2011 |
June 2011 |
July 29, 2008 |
July 22, 2016 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - University of California
San Diego, California, United States - Colorado Neurological Institute
Littleton, Colorado, United States - (and 25 more...)
|
| 30 |
NCT00665223 |
Completed |
A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease |
|
|
Interventional |
Phase 3 |
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary objective is to assess the effects of ACR16 on voluntary motor function in HD patients, as defined as the sum score of items 4-10 and 13-15 of the UHDRS motor assessment (a modified motor score mMS) at 26 weeks of treatment.
- Safety and tolerability assessed from adverse event profile.
- The effects of ACR16 on CGI, cognitive function, behaviour and symptoms of depression and anxiety.
|
437 |
All |
30 Years and older (Adult, Senior) |
NCT00665223 |
ACR16 C008 |
MermaiHD |
April 2008 |
June 2011 |
June 2011 |
April 23, 2008 |
July 21, 2016 |
|
- LKH -Univ. Klinikum Graz, Universitaetsklinik fur Psychiatrie Graz
Graz, Styria, Austria - Innsbruck Medical University, Anichstraße 35
Innsbruck, Tyrol, Austria - University Hospital Gasthuisberg
Leuven, Flemish Brabant, Belgium - (and 28 more...)
|
| 31 |
NCT02855476 |
Recruiting |
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease |
|
|
Observational |
|
- University College, London
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of CSF samples banked
- Huntingtin protein level in cerebrospinal fluid
- Kynurenine metabolites in cerebrospinal fluid
|
600 |
All |
21 Years to 75 Years (Adult, Senior) |
NCT02855476 |
15/0519 |
HDClarity |
January 2017 |
July 2019 |
July 2020 |
August 4, 2016 |
March 19, 2018 |
|
- John Hopkins University
Baltimore, Maryland, United States - Wake Forest University
Winston-Salem, North Carolina, United States - University of British Columbia, The Centre for Huntingtons Disease
Vancouver, British Columbia, Canada - (and 9 more...)
|
| 32 |
NCT01937923 |
Completed |
A Pre-Cellular Therapy Observational Study in Early Huntington's Disease |
|
|
Observational |
|
- University of California, Davis
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rate of change from baseline in white matter volume on magnetic resonance imaging (MRI) brain scan.
- Rate of change from baseline on the UHDRS total motor score
- Rate of change from baseline on the Total Functional Capacity score
|
29 |
All |
18 Years and older (Adult, Senior) |
NCT01937923 |
455690
DR2A-05415 |
PRE-CELL |
August 2013 |
July 2016 |
July 2016 |
September 10, 2013 |
November 1, 2016 |
|
- UC Davis Medical Center, Clinical Research Center
Sacramento, California, United States
|
| 33 |
NCT02990676 |
Recruiting |
Exploring Computerised Cognitive Training for People With Huntington's Disease |
|
- Behavioral: Computerised cognitive training
|
Interventional |
Not Applicable |
- Cardiff University
- Jacque and Gloria Gossweiler Foundation
- Health and Care Research Wales
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Number of participants able to complete the feasibility study as measured by retention rate
- Number of participants able to complete computerised HAPPYneuron pro cognitive training as assessed by task performance and the quality of the data generated.
- Symbol digit modality test
- (and 14 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02990676 |
1535-16
HF-16-1152
210821 |
CogTrainHD |
January 25, 2017 |
September 2019 |
September 2019 |
December 13, 2016 |
January 30, 2018 |
|
- Cardiff University
Cardiff, United Kingdom
|
| 34 |
NCT01735981 |
Completed |
The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington's Disease |
|
- Other: Video game exercise using Dance Dance Revolution
- Other: hand-held video game
|
Interventional |
Not Applicable |
- Anne Kloos
- Ohio State University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- gait parameters
- Tinetti Mobility Test
- Four Square Step Test
- (and 4 more...)
|
24 |
All |
18 Years to 79 Years (Adult, Senior) |
NCT01735981 |
2008H0109 |
|
June 2008 |
November 2010 |
June 2012 |
November 28, 2012 |
November 28, 2012 |
|
- The Ohio State University Atwell Hall
Columbus, Ohio, United States
|
| 35 |
NCT01458470 |
Completed |
A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease |
|
- Drug: Memantine
- Other: Placebo
|
Interventional |
Phase 2 |
- University of British Columbia
- Huntington Society of Canada
- Huntington Study Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Utility of TRACK-HD study endpoints in a clinical trial setting
- Neuropsychiatric and Cognitive Test Scores
|
19 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01458470 |
H11-01364 |
MITIGATE-HD |
September 2011 |
August 2012 |
November 2012 |
October 24, 2011 |
March 18, 2014 |
|
- The Centre for Huntington Disease
Vancouver, British Columbia, Canada
|
| 36 |
NCT02550275 |
Unknown † |
Social Cognition in Huntington's Disease: Cognitive Study and Functional and Morphological Imaging |
|
- Behavioral: neuropsychological test
- Radiation: MRI
|
Interventional |
Not Applicable |
- University Hospital, Angers
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- the achievement of social cognition process in Huntington's disease using the total score of the scale 15-TOM
|
80 |
All |
20 Years to 70 Years (Adult, Senior) |
NCT02550275 |
AOI 201409 |
COSIMH |
January 2015 |
February 2018 |
|
September 15, 2015 |
September 15, 2015 |
|
|
| 37 |
NCT01411150 |
Completed |
Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study |
|
- Drug: Creatine Monohydrate
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
- National Institutes of Health (NIH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety
- Tolerability
- Clinical measures
- Biological Markers of Disease Progression
|
38 |
All |
26 Years and older (Adult, Senior) |
NCT01411150 |
2009P000642 |
Pre-CREST-X |
May 2009 |
September 2012 |
September 2012 |
August 8, 2011 |
February 10, 2014 |
|
- Massachusetts General Hospital
Charlestown, Massachusetts, United States
|
| 38 |
NCT01411163 |
Completed |
Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability |
|
- Drug: Creatine monohydrate
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
- National Institutes of Health (NIH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety
- Tolerability
- Clinical measures
- Biological Markers of Disease Progression
|
24 |
All |
26 Years and older (Adult, Senior) |
NCT01411163 |
2010P000511 |
Pre-CREST-2X |
April 2010 |
May 2013 |
May 2013 |
August 8, 2011 |
February 10, 2014 |
|
- Massachusetts General Hospital
Charlestown, Massachusetts, United States
|
| 39 |
NCT00387270 |
Completed |
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease |
|
|
Interventional |
Phase 1
Phase 2 |
- Medivation, Inc.
- Huntington Study Group
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicities
- Unified Huntington's Disease Rating Scale
|
9 |
All |
18 Years and older (Adult, Senior) |
NCT00387270 |
DIM03
DIMOND |
|
October 2006 |
March 2007 |
March 2007 |
October 12, 2006 |
January 4, 2008 |
|
- Huntington Study Group
Rochester, New York, United States
|
| 40 |
NCT03225846 |
Recruiting |
Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease |
|
- Drug: WVE-120102
- Drug: Placebo
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Safety: Number of patients with adverse events (AEs)
- Safety: Severity of AEs
- Safety: Number of patients with serious AEs (SAEs)
- (and 7 more...)
|
48 |
All |
25 Years to 65 Years (Adult) |
NCT03225846 |
WVE-HDSNP2-001 |
PRECISION-HD2 |
July 17, 2017 |
September 2019 |
September 2019 |
July 21, 2017 |
March 27, 2018 |
|
- Centre For Movement Disorders
Toronto, Ontario, Canada - Szpital Sw. Wojciecha
Gdańsk, Poland - Instytut Psychiatrii i Neurologii
Warsaw, Poland
|
| 41 |
NCT03225833 |
Recruiting |
Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease |
|
- Drug: WVE-120101
- Drug: Placebo
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Safety: Number of patients with adverse events (AEs)
- Safety: Severity of AEs
- Safety: Number of patients with serious AEs (SAEs)
- (and 7 more...)
|
48 |
All |
25 Years to 65 Years (Adult) |
NCT03225833 |
WVE-HDSNP1-001 |
PRECISION-HD1 |
July 17, 2017 |
September 2019 |
September 2019 |
July 21, 2017 |
March 27, 2018 |
|
- Centre For Movement Disorders
Toronto, Ontario, Canada - Szpital Sw. Wojciecha
Gdańsk, Poland - Instytut Psychiatrii i Neurologii
Warsaw, Poland
|
| 42 |
NCT01412151 |
Completed
Has Results |
Creatine Safety & Tolerability in Huntington's Disease |
- Huntington's Disease (HD)
|
- Drug: Creatine monohydrate
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tolerability
- Clinical Measures Resources Not Available to Complete Secondary Analyses.
- Biological Markers of Disease Progression
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT01412151 |
2005P000530 |
CREST-X |
April 2005 |
November 2011 |
November 2011 |
August 9, 2011 |
March 9, 2018 |
December 28, 2012 |
- Massachusetts General Hospital
Charlestown, Massachusetts, United States
|
| 43 |
NCT00980694 |
Completed |
Bioavailability of Ubiquinol in Huntington Disease |
|
- Dietary Supplement: ubiquinol
|
Interventional |
Phase 1 |
- University of Rochester
- Kaneka Corporation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- serum coenzyme Q10 levels
|
6 |
All |
18 Years and older (Adult, Senior) |
NCT00980694 |
UQ01 |
|
September 2009 |
July 2012 |
July 2012 |
September 21, 2009 |
May 27, 2016 |
|
- University of Rochester
Rochester, New York, United States
|
| 44 |
NCT00075140 |
Completed |
Family Health After Predictive Huntington Disease (HD) Testing |
|
- Genetic: Mutation in the gene
|
Observational |
|
- National Institute of Nursing Research (NINR)
|
NIH |
|
- Impact of a positive HD test or presence of HD on a family members perceptions of: health problems, emotional and functional health status, resources/strategies for managing problems, helpfulness, and services needed to help family members cope.
- Describe the health care needs, management strategies, and needs for health and social services of a broader sample of relatives/significant others in families in which a person has a gene mutation for HD.
|
422 |
All |
Child, Adult, Senior |
NCT00075140 |
1R01NR007970-01 |
|
September 2001 |
October 2008 |
October 2008 |
January 5, 2004 |
January 16, 2009 |
|
- The University of Iowa College of Nursing
Iowa City, Iowa, United States
|
| 45 |
NCT02956148 |
Recruiting |
Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers |
|
- Radiation: Radioligand [18F]MNI-659
|
Interventional |
Early Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- The longitudinal changes of PDE10A enzyme availability in the caudate, putamen, and globus pallidus of Huntington's Disease Gene Expansion Carriers by comparison of the follow-up and initial PET measurements.
|
45 |
All |
18 Years to 73 Years (Adult, Senior) |
NCT02956148 |
CHDIKI1401 |
LONGPDE10 |
June 2015 |
June 2018 |
September 2018 |
November 7, 2016 |
November 7, 2016 |
|
- The Memory Clinic, Rigshopitalet
Copenhagen, Denmark - Leiden University Medical Center, Department of Neurology
Leiden, Netherlands - University of Oslo, Nevrologisk poliklinikk
Oslo, Norway - (and 4 more...)
|
| 46 |
NCT02336633 |
Recruiting |
Resveratrol and Huntington Disease |
|
- Dietary Supplement: Resveratrol
- Other: Placebo
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- rate of caudate atrophy
- UHDRS (Unified Huntington Disease Rating Scale)
- TFC (Total Functional Capacity)
- ratio of inorganic phosphate/phosphocreatine
|
102 |
All |
18 Years and older (Adult, Senior) |
NCT02336633 |
P130918 |
REVHD |
July 2015 |
January 2019 |
January 2019 |
January 13, 2015 |
April 17, 2018 |
|
- Institut du Cerveau et de la Moelle, Hôpital de la Pitié Salpêtrière
Paris, France
|
| 47 |
NCT03344601 |
Recruiting |
PHysical Activity and Exercise Outcomes in Huntington's Disease |
|
- Behavioral: physical activity
|
Interventional |
Not Applicable |
- Cardiff University
- CHDI Foundation, Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Data completeness
- Recruitment
- Retention
- (and 16 more...)
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT03344601 |
SPON 1631-17 |
PACE-HD |
February 16, 2018 |
October 16, 2019 |
December 31, 2019 |
November 17, 2017 |
March 6, 2018 |
|
- Re+Active Therapy and Wellness Centre/ UCLA
Los Angeles, California, United States - Teacher's College, Columbia University
New York, New York, United States - George Huntington Institute
Münster, Germany - (and 3 more...)
|
| 48 |
NCT02481674 |
Recruiting |
VX15/2503 Treatment for Huntington's Disease |
|
- Drug: VX15/2503
- Drug: Placebo
|
Interventional |
Phase 2 |
- Vaccinex Inc.
- Huntington Study Group
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety and tolerability as measured by drug related adverse event frequency and laboratory test abnormalities
- Immunogenicity of VX15/2503 as measured by the frequency and titer of anti-drug antibodies
- Brain volumes measured by MRII
- (and 13 more...)
|
240 |
All |
21 Years and older (Adult, Senior) |
NCT02481674 |
VX15/2503-N-131 |
SIGNAL |
July 2015 |
May 2020 |
May 2020 |
June 25, 2015 |
October 13, 2017 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - University of California, San Diego
La Jolla, California, United States - University of Colorado - Denver
Aurora, Colorado, United States - (and 16 more...)
|
| 49 |
NCT02464293 |
Active, not recruiting |
A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease |
|
- Other: Mindfulness-based cognitive therapy
|
Interventional |
Not Applicable |
- Lancaster University
- Manchester University NHS Foundation Trust
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- depression post intervention
- depression at 3 months
- depression at 1 year
- (and 29 more...)
|
16 |
All |
18 Years and older (Adult, Senior) |
NCT02464293 |
EHDN Seed Fund Project 561
15/NW/0238 |
|
June 2015 |
December 2017 |
May 2018 |
June 8, 2015 |
June 2, 2017 |
|
- Central Manchester University Hospitals NHS Foundation Trust
Manchester, United Kingdom
|
| 50 |
NCT00277355 |
Completed
Has Results |
Pilot Study of Minocycline in Huntington's Disease |
|
- Drug: minocycline
- Drug: Matching placebo
|
Interventional |
Phase 2
Phase 3 |
- Merit Cudkowicz
- FDA Office of Orphan Products Development
- Huntington Study Group
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method]
- Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [Regression Based Multiple Imputation Method]
|
114 |
All |
18 Years and older (Adult, Senior) |
NCT00277355 |
FD-R-002588
DOMINO |
|
April 2006 |
October 2008 |
November 2008 |
January 16, 2006 |
April 19, 2013 |
April 19, 2013 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Colorado Neurological Institute
Englewood, Colorado, United States - University of Florida
Gainesville, Florida, United States - (and 9 more...)
|
Create an RSS feed from your search for:
Download the search results for: